Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD)

CoMentis

Status and phase: Terminated; Phase 2

Conditions: Macular Degeneration

Treatments: Drug: Placebo; Drug: Mecamylamine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00414206

ATG003-201

Details and patient eligibility

About

This is a Phase II randomized, double-masked study comparing the safety and efficacy of ATG003 (mecamylamine HCl) 1.0% and 0.3% ophthalmic solutions to placebo in patients with neovascular ("wet") age-related macular degeneration (NV-AMD).

Enrollment: 343 patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

343 participants in 3 patient groups, including a placebo group

1% mecamylamine

Active Comparator group

Treatment:

Drug: Mecamylamine

0.3% mecamylamine

Active Comparator group

Treatment:

Drug: Mecamylamine

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo